STANDARD BIOTOOLS INC SEC Filings

Standard BioTools Inc. is registering 17,400,000 shares of common stock for issuance under its Amended and Restated 2011 Equity Incentive Plan, as amended. These additional shares are reserved for employee equity awards under the 2011 Plan, which was made effective as of June 18, 2025. The company is using this Form S-8 to add to a long-standing plan, incorporating by reference multiple prior S-8 registrations related to the same equity incentive program.

Standard BioTools (LAB) disclosed classification and accounting for the previously announced sale of its SomaScan Business as a discontinued operation. The agreed sale proceeds total $350.0 million plus estimated contingent consideration with an estimated fair value of $396.9 million; the fair value of consideration transferred in the Merger was reported as $444.2 million, and the company recognized a $25.2 million bargain purchase gain. The company allocated $111.9 million of goodwill (100% of total goodwill) to the discontinued operations based on relative fair value, and $30.0 million of deferred revenue related to a Collaboration Agreement was excluded from the disposal group. Management performed recoverability testing on remaining long-lived assets and did not recognize impairment for the periods presented. The filing also discloses continued investments in R&D and commercial infrastructure, a share repurchase authorization up to 50.0 million common shares through March 1, 2026, and maintenance of a valuation allowance against U.S. deferred tax assets.

Standard BioTools Inc. (LAB) furnished a Current Report on Form 8-K stating it issued a press release dated August 11, 2025 that includes information about certain financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1.

The filing specifies that the press release content, excluding the sections titled "Full Year 2025 Revenue Outlook" and "About Standard BioTools Inc." together with the forward-looking statement disclaimer, is incorporated by reference into Item 2.02, while those excluded sections and the disclaimer are incorporated by reference into Item 7.01. The report is furnished, not filed, and is signed by Alex Kim, Chief Financial Officer.

Standard BioTools Inc. (LAB) – Form 4/A (filed 07/30/25)

Director Troy Cox filed an amended Form 4 to correct the share count shown in Column 5 of Table I of the original filing dated 06/24/25. After the correction, Cox is shown as beneficially owning 319,322 shares of LAB common stock. No new acquisitions, dispositions, option exercises, or derivative positions are reported; the filing strictly updates the post-transaction ownership figure. All other data from the original Form 4 remain unchanged. Because the amendment merely revises record-keeping and does not reflect a new transaction, the disclosure is administrative in nature and has negligible economic impact on shareholder value or float.

Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.

Following these grants, Cox’s beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.

Standard BioTools Inc. (LAB) has reported insider equity awards to Director Fenel M. Eloi on Form 4 dated 06/24/2025. On 06/20/2025 Eloi received 94,592 Restricted Stock Units (RSUs) valued at $0 per unit and 125,660 non-qualified stock options with an exercise price of $1.05 per share. The RSUs vest in full on the earlier of 20 June 2026 or one day before the next annual meeting, while the options vest in twelve equal monthly tranches beginning 20 July 2025 and expire 20 June 2035.

After these grants, Eloi’s direct holdings increase to 236,183 common shares and 125,660 options. The transaction code “A” indicates the shares and options were awarded by the company rather than purchased on the open market. No Rule 10b5-1 trading plan was noted, and the filing concerns routine director compensation rather than open-market buying or selling.